Assessing Tab-Cel for EBV+ Post-Transplant Lymphoproliferative Disease

Article

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed data from the ALLELE study to be presented at ASH 2021.

“What we're reporting at the ASH meeting is the first interim results from the ALLELE study. Specifically, we're bringing on a population of patients that had received therapy, that we have overall response rate for by independent oncologic radiographic assessment. And then they have also had an opportunity for 6 months follow up so we can really see the durability response in our population.”

Atara Biotherapeutics is reporting updated data from the phase 3 ALLELE study (NCT03394365) of tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) at the upcoming American Society of Hematology 2021 Meeting, December 11-14. 

The ALLELE study has enrolled 38 evaluable, heavily pretreated patients with EBV+ PTLD as of May 2021. Independent objective response rate was 50% (95% CI [33.4, 66.6]; n = 19). Median time to response was 1.1 months (range, 0.7-4.7). Eleven patients had a duration of response of at least 6 months. No new safety signals or concerns were reported, and safety findings were consistent with previously published data.

GeneTherapyLive spoke with AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, to learn more about the ALLELE study and the positive data seen in enrolled participants.

REFERENCE
Atara Biotherapeutics to present eight abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, including first presentation of Tab-cel® pivotal phase 3 (ALLELE) data. News release. Atara Biotherapeutics. November 4, 2021. https://www.businesswire.com/news/home/20211104005811/en/Atara-Biotherapeutics-to-Present-Eight-Abstracts-at-the-63rd-American-Society-of-Hematology-ASH-Annual-Meeting-Including-First-Presentation-of-Tab-cel%C2%AE-Pivotal-Phase-3-ALLELE-Data
Related Videos
Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
© 2024 MJH Life Sciences

All rights reserved.